​

NRx Pharmaceuticals Stock (NASDAQ:NRXP)

ForecastRevenueOwnershipFinancialsChartTranscripts
NRx Pharmaceuticals by TradingView

Previous Close

$3.76

52W Range

$1.62 - $5.05

50D Avg

$3.17

200D Avg

$2.62

Market Cap

$67.76M

Avg Vol (3M)

$1.28M

Beta

2.19

Div Yield

-

NRXP Company Profile

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Dec 04, 2017

Website

NRXP Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25
Therapy$854.00K

Fiscal year ends in Dec 25 | Currency in USD

NRXP Financial Summary

Dec 25Dec 24Dec 23
Revenue$1.23M--
Operating Income$-16.22M$-19.70M$-27.59M
Net Income$-28.62M$-25.13M$-30.15M
EBITDA$-16.15M$-24.04M$-30.02M
Basic EPS$-1.34$-2.39$-3.98
Diluted EPS$-1.34$-2.39$-3.98

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 24, 26 | 8:00 AM
Q3 25Nov 17, 25 | 8:30 AM
Q2 25Aug 20, 25 | 8:00 AM

Peer Comparison

TickerCompany
COEPCoeptis Therapeutics, Inc.
CUECue Biopharma, Inc.
OTLKOutlook Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
SPRBSpruce Biosciences, Inc.
IOBTIO Biotech, Inc.
SNTISenti Biosciences, Inc.
EQEquillium, Inc.
HOWLWerewolf Therapeutics, Inc.
KPTIKaryopharm Therapeutics Inc.